Name
GS01-12 - MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer (China)
Date & Time
Wednesday, December 20, 2023
Speakers
Virtual Session Link